Should You Buy Alterity Therapeutics Limited Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Alterity Therapeutics Limited (ATHE) occupies a solid middle-ground position with a Quality of Company score of 6.2/10. At the current market price of $3.50, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 0 of 0 CirclFi valuation models project upside for Alterity Therapeutics Limited (ATHE) at $3.50 — the models are evenly split, with a Quality Score of 6.2/10 and Value-Trap risk of 32/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Alterity Therapeutics Limited (ATHE) in 2026?
What Is the Bull Case vs the Bear Case for Alterity Therapeutics Limited (ATHE)?
| Bull case | Bear case |
|---|---|
| No active model projects meaningful upside for ATHE at $3.50. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | No active model flags significant downside for ATHE. The Value Trap score of 32/100 still argues for some caution. |
How Does ATHE Compare to Its Biotechnology Peers?
Valuation data pages: CRDF · MGNX · LEXX · VYGR · CDXS · DTIL · IMVT · BCTX · CLGN · EXEL · INCY
Which Other Stocks Score Like ATHE on Quality?
Closest companies to ATHE’s Quality of Company score of 6.2/10, across all industries.
- YYAI — AiRWA Inc. (QOC 6.2) · analysis
- IPM — Intelligent Protection Management Corp. (QOC 6.2) · analysis
- TAC — TransAlta Corporation (QOC 6.2) · analysis
- DXLG — Destination XL Group, Inc. (QOC 6.2) · analysis
- WSBK — Winchester Bancorp, Inc. (QOC 6.2) · analysis
- SPIR — Spire Global, Inc. (QOC 6.2) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does ATHE Appear In?
So Is Alterity Therapeutics Limited (ATHE) Worth Buying in 2026?
Alterity Therapeutics Limited currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.
These are quantitative model outputs, not investment recommendations. Alterity Therapeutics Limited's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ATHE Stock?
Should I buy ATHE stock right now?
Based on CirclFi's multi-model analysis, 0 of 0 models see upside for ATHE at $3.50. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Alterity Therapeutics Limited?
Key risks include: limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does ATHE compare to its competitors?
Among Biotechnology peers, ATHE holds a Quality Score of 6.2/10. Comparable companies include CRDF (QOC 6.2), MGNX (QOC 6.2), LEXX (QOC 6.2). The relative ranking helps investors identify whether ATHE offers better fundamental quality than alternatives in the same sector.
Is ATHE a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ATHE's Quality Score of 6.2/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy ATHE at?
CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ATHE.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad